Recruiting
Early Phase 1

Aspirin

Sponsor:

NYU Langone Health

Code:

NCT07525635

Conditions

Preeclampsia Possible

Eligibility Criteria

Sex: Female

Age: 18 - 50

Healthy Volunteers: Not accepted

Interventions

Aspirin

Study Details

Brief summary:

The purpose of this study is assess platelet phenotypes based on aspirin dosing in pregnant patients at risk for the development preeclampsia who are taking 81mg twice a day aspirin. Blood samples will be collected approximately 4 weeks after initiation of aspirin to evaluate the platelet phenotype during pregnancy in patients.

Conditions

Preeclampsia Possible

Study ID

NCT07525635

Start date

Apr 27, 2026

Status verified date

Apr, 2026

Completion date

Feb 20, 2028

Anticipated

Primary completion date

Aug 1, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Female

Age: 18 - 50

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Pregnant people prior to 17 weeks
  • Prenatal care at NYU Langone Health Obstetrics and Gynecology Associates
  • Age 18-50 years
  • Singleton viable gestation
  • Pregnant patients at high risk of preeclampsia: Patients meeting USPSTF recommendation for aspirin prophylaxis for preeclampsia based on clinical risk factors.

Exclusion Criteria:

  • Undergoing glucose challenge test (GCT) at time of blood draw
  • Allergy or intolerance to aspirin
  • Antithrombotic or antiplatelet therapy
  • Anemia (hemoglobin <10 g/dl) or thrombocytopenia (platelet count <100,000), or thrombocytosis (platelet count >600,000)
  • Known hemorrhagic diathesis
  • Planned delivery outside of NYU

Study Design

Enrollment

30 participants

Anticipated

Intervention Model

Single group

Primary purpose

Prevention

Interventions and Outcome Measures

Arms

experimental: Twice daily dosing of Aspirin

Participants will take 81mg Aspirin orally, twice daily (162mg total) for 4 weeks and then return to the dosing regimen as prescribed by the discretion of their treating physician.

Interventions

Aspirin

81mg twice a day (162mg total)

Primary outcome measure

  • Measures of platelet aggregation assessed by Light Transmission Aggregometry (LTA) [ Time Frame: Baseline, 4 weeks after initiation of aspirin ]

Central Contacts and Locations

Central contacts

Christina A. Penfield, MD, MPH

646-754-2700Christina.Penfield@nyulangone.org

Lucia Muzzarelli

646-754-2760Lucia.Muzzarelli@nyulangone.org

Locations

NYU Langone Health

Recruiting

New York, New York, United States, 10016

More Information

Sponsor

NYU Langone Health

Last update posted

May 18, 2026

Last verified

Apr, 2026

Keywords

  • Asprin
  • Pregnancy

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by NYU Langone Health on 2026-05-18.